Research ArticleOncology
Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E. Mortimer, James R. Bading, Jinha M. Park, Paul H. Frankel, Mary I. Carroll, Tri T. Tran, Erasmus K. Poku, Russell C. Rockne, Andrew A. Raubitschek, John E. Shively and David M. Colcher
Journal of Nuclear Medicine January 2018, 59 (1) 38-43; DOI: https://doi.org/10.2967/jnumed.117.193888
Joanne E. Mortimer
1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
James R. Bading
1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
Jinha M. Park
2Department of Radiology, City of Hope, Duarte, California
Paul H. Frankel
3Department of Information Sciences, City of Hope, Duarte, California
Mary I. Carroll
1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
Tri T. Tran
2Department of Radiology, City of Hope, Duarte, California
Erasmus K. Poku
4Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and
Russell C. Rockne
3Department of Information Sciences, City of Hope, Duarte, California
Andrew A. Raubitschek
4Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and
John E. Shively
5Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, California
David M. Colcher
4Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 1
January 1, 2018
Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E. Mortimer, James R. Bading, Jinha M. Park, Paul H. Frankel, Mary I. Carroll, Tri T. Tran, Erasmus K. Poku, Russell C. Rockne, Andrew A. Raubitschek, John E. Shively, David M. Colcher
Journal of Nuclear Medicine Jan 2018, 59 (1) 38-43; DOI: 10.2967/jnumed.117.193888
Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E. Mortimer, James R. Bading, Jinha M. Park, Paul H. Frankel, Mary I. Carroll, Tri T. Tran, Erasmus K. Poku, Russell C. Rockne, Andrew A. Raubitschek, John E. Shively, David M. Colcher
Journal of Nuclear Medicine Jan 2018, 59 (1) 38-43; DOI: 10.2967/jnumed.117.193888
Jump to section
Related Articles
Cited By...
- Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
- Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study
- Towards integration of 64Cu-DOTA-Trasztusumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer
- Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
- Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA
- PET Imaging of Receptor Tyrosine Kinases in Cancer